Neurocrine Financial Expectations for 2024

 

INGREZZA® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion, Representing Year-over-Year Growth of 25% and 29% Respectively INGREZZA® (valbenazine) Full Year 2024 Net Product Sales Guidance of $2.1 - $2.2 Billion Crinecerfont FDA Regulatory Submission Anticipated in the Second Quarter for the Treatment of Congenital Adrenal Hyperplasia in Adults and Pediatrics https://www.biospace.com/article/releases/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2023-financial-results-and-provides-financial-expectations-for-2024/